News

Trastuzumab/Pertuzumab Doublet Eradicates Some Early Breast Cancer

Publish date: December 10, 2010

 

FROM THE SAN ANTONIO BREAST CANCER SYMPOSIUM

* CORRECTION, 12/16/2010: The original version of this article misidentified the brand name for pertuzumab. The correct brand name is Omnitarg. This version has been updated.

Pages

Recommended Reading

Screening Mammography Rates Are Below Guideline Recommendations
MDedge Internal Medicine
More Seasonal Flu Strains Show Worrisome Dual Antiviral Resistance
MDedge Internal Medicine
Operative Time Plays a Big Role in Hysterectomy Cost
MDedge Internal Medicine
FDA Panel Supports Combination for Weight Loss
MDedge Internal Medicine
Buprenorphine Offers Alternative to Methadone During Pregnancy
MDedge Internal Medicine
Girls' Soccer Second to Football for High School Sports Concussion
MDedge Internal Medicine
Nurses' Health Study Data Did Not Change Surgical Practice
MDedge Internal Medicine
Severe Incontinence More Likely to Respond to Transurethral Bulking Agent
MDedge Internal Medicine
Zoledronic Acid Sinks as Breast Cancer Therapy in AZURE Trial
MDedge Internal Medicine
Obesity Linked to Worse Outcomes in Common Breast Cancer Subtype
MDedge Internal Medicine